Prevalence of serological markers of autoimmunity in hemodialysis patients with hepatitis C virus
Prevalence of serological markers of autoimmunity in hemodialysis patients with hepatitis C virus
复制标题
DOI：
10.1016/s0041-1345(98)00074-8
复制
发表时间：
1998-05-01
影响因子：
0.9
通讯作者：
Bilgin, N
中科院分区：
文献类型：
--
作者：
Özdemir, FN;Turan, M;Bilgin, N
许多研究表明，血液透析患者感染丙型肝炎病毒（HCV）的风险很高。这种疾病在这些患者中通常是无症状的，但慢性HCV感染与几种肝外免疫疾病有关：原发性混合性冷球蛋白血症，迟发性皮肤卟啉症，膜增生性肾小球肾炎，自身免疫性甲状腺炎和干燥综合征。抗核抗体（ANA）、平滑肌细胞抗体（SMA）和类风湿因子（RF）的血清学检测在慢性HCV感染患者中已发现阳性。干扰素-α（IFN-α）是治疗HCV感染的重要选择之一，但治疗后经常复发。然而，某些患有冷球蛋白血症和其他类似特征的患者是成功治疗的患者。在这项研究中，我们调查了抗HCV（+）血液透析患者中自身抗体的患病率，并将这些发现与抗HCV（-）患者进行了比较。我们还研究了HCV-RNA阳性和INF-α治疗相对于自身抗体发生的重要性。
MANY investigators have shown that hemodialysis patients are at high risk for hepatitis C virus (HCV) infection. This illness is usually asymptomatic in these patients, but chronic HCV infection has been associated with several extrahepatic immunologic conditions: essential mixed cryoglobulinemia, porphyria cutanea tarda, membranoproliferative glomerulonephritis, autoimmune thyroiditis, and Sjogren syndrome. Positive serologic tests for anti-nuclear antibodies (ANA), smooth muscle cell antibodies (SMA), and rheumatoid factor (RF) have been found in patients with chronic HCV infection. Interferon-alpha (INF-α) is the one of the important treatment options for HCV infection, although frequent relapse has been observed after therapy. Certain patients with cryoglobulinemia and other similar features are among those who have been treated successfully, however. In this study, we investigated the prevalence of autoantibodies in anti-HCV (+) hemodialysis patients and compared these findings to those in anti-HCV (-) patients. We also studied the importance of HCV-RNA positivity and INF-α treatment relative to the occurrence of autoantibodies.